Sanofi adds diabetes to collaborative effort at UCSF

Sanofi ($SNY) is broadening its research ties with the University of California in San Francisco, which has been steadily growing its collaborative work with the biopharma industry under Chancellor Susan Desmond-Hellmann. In the new $3.1 million pact, Sanofi researchers will work with investigators on new treatments for diabetes. Scientists are already joining forces with Sanofi on brain trauma and oncology. Release

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.